Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Tian, Daiyin ^a,b   Battles, Michael B ^c   Moin, Syed M ^a   Chen, Man ^a   Modjarrad, Kayvon ^d,e   Kumar, Azad ^a   Kanekiyo, Masaru ^a   Graepel, Kevin W ^f   Taher, Noor M ^c   Hotard, Anne L ^g,i   Moore, Martin L ^g,j   Zhao, Min ^h   Zheng, Zi Zheng ^h   Xia, Ning Shao ^h,i   McLellan, Jason S ^c   Graham, Barney S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b CHILDREN S HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^e HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h XIAMEN UNIVERSITY   (China)

ⁱ CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^j Meissa Vaccines   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 C 4 ANTIBODY; ANTIBODY; D 25 ANTIBODY; GLYCOPROTEIN; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; ANTIVIRUS AGENT; NEUTRALIZING ANTIBODY; PALIVIZUMAB; PROTEIN BINDING; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS ANTIBODY;

ANTIBODY; IMMUNITY; NEUTRALIZATION; PROTEIN; RESPIRATION; VACCINE; VIRUS;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CRYSTAL STRUCTURE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; MUTAGENESIS; NEXT GENERATION SEQUENCING; NONHUMAN; PROTEIN EXPRESSION; VIROLOGY; VIRUS NEUTRALIZATION; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY;

RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; ANTIVIRAL AGENTS; CRYSTALLOGRAPHY, X-RAY; HEK293 CELLS; HUMANS; PALIVIZUMAB; PROTEIN BINDING; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SURFACE PLASMON RESONANCE; VIRAL FUSION PROTEINS;

EID: 85037054168     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-01858-w     Document Type: Article

References (37)

1. Nair, H. et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and metaanalysis. Lancet 375, 1545-1555 (2010).
2. Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095-2128 (2012).
3. Glezen, W. P., Taber, L. H., Frank, A. L. & Kasel, J. A. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Children 140, 543-546 (1986).
4. Hall, C. B. et al. The burden of respiratory syncytial virus infection in young children. N. Eng. J. Med. 360, 588-598 (2009).
5. Mufson, M. A., Orvell, C., Rafnar, B. & Norrby, E. Two distinct subtypes of human respiratory syncytial virus. J. Gen. Virol. 66(Pt 10), 2111-2124 (1985).
6. Hendry, R. M. et al. Concurrent circulation of antigenically distinct strains of respiratory syncytial virus during community outbreaks. J. Infect. Dis. 153, 291-297 (1986).
7. Hall, C. B. et al. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J. Infect. Dis. 162, 1283-1290 (1990).
8. Gilca, R. et al. Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons. J. Infect. Dis. 193, 54-58 (2006).
9. Martinello, R. A., Chen, M. D., Weibel, C. & Kahn, J. S. Correlation between respiratory syncytial virus genotype and severity of illness. J. Infect. Dis. 186, 839-842 (2002).
10. Devincenzo, J. P. Natural infection of infants with respiratory syncytial virus subgroups A and B: a study of frequency, disease severity, and viral load. Pediatr. Res. 56, 914-917 (2004).
11. Melero, J. A. & Moore, M. L. Influence of respiratory syncytial virus strain differences on pathogenesis and immunity. Curr. Top. Microbiol. Immunol. 372, 59-82 (2013).
12. Collins, P. L., Fearns, R. & Graham, B. S. Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr. Top. Microbiol. Immunol. 372, 3-38 (2013).
13. McLellan, J. S. et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340, 1113-1117 (2013).
14. Gilman, M. S. et al. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci. Immunol. 1, https://doi. org/10.1126/sciimmunol.aaj1879 (2016).
15. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102, 531-537 (1998).
16. Corti, D. et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 501, 439-443 (2013).
17. Zheng, Z. Z. et al. Epitope of rsv fusion protein and antibody recognizing the same. United States patent (2016).
18. Kwakkenbos, M. J. et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat. Med. 16, 123-128 (2010).
19. Ngwuta, J. O. et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci. Transl. Med. 7, 309ra162 (2015).
20. Krarup, A. et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat. Commun. 6, 8143 (2015).
21. Lawrence, M. C. & Colman, P. M. Shape complementarity at protein/protein interfaces. J. Mol. Biol. 234, 946-950 (1993).
22. Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774-797 (2007).
23. McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592-598 (2013).
24. Kong, L. et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 20, 796-gp803 (2013).
25. Tang, X. et al. Structural basis for the neutralization and genotype specificity of hepatitis E virus. Proc. Natl Acad. Sci. USA 108, 10266-10271 (2011).
26. Sande, C. J., Mutunga, M. N., Medley, G. F., Cane, P. A. & Nokes, D. J. Groupand genotype-specific neutralizing antibody responses against respiratory syncytial virus in infants and young children with severe pneumonia. J. Infect. Dis. 207, 489-492 (2013).
27. D'Arcy, A., Villard, F. & Marsh, M. An automated microseed matrix-screening method for protein crystallization. Acta. Crystallogr. D Biol. Crystallogr. 63, 550-554 (2007).
28. Battye, T. G., Kontogiannis, L., Johnson, O., Powell, H. R. & Leslie, A. G. iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr. D Biol. Crystallogr. 67, 271-281 (2011).
29. Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution? Acta. Crystallogr. D Biol. Crystallogr. 69, 1204-1214 (2013).
30. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
31. Zhu, J. et al. Structure-guided design of a high-affinity platelet integrin alphaIIbbeta3 receptor antagonist that disrupts Mg(2)(+) binding to the MIDAS. Sci. Transl. Med. 4, 125ra132 (2012).
32. Potter, J. A. et al. Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. J. Virol. 86, 12923-12932 (2012).
33. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta. Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
34. Adams, P. D. et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. Sect. D Biol. crystallogr. 58, (1948-1954 (2002).
35. Barouch, D. H. et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J. Virol. 79, 8828-8834 (2005).
36. Hotard, A. L. et al. A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology 434, 129-136 (2012).
37. Buchholz, U. J., Finke, S. & Conzelmann, K. K. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J. Virol. 73, 251-259 (1999).